Arvinas (ARVN) Income from Continuing Operations (2017 - 2026)
Arvinas' (ARVN) quarterly Income from Continuing Operations came in at 57600000.0 in Q1 2026, down 169.48% year-on-year from 82900000.0 in Q1 2025, and up 14.54% quarter-over-quarter from 67400000.0 in Q4 2025.
Arvinas (ARVN) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Arvinas' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 57600000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations fell 169.48% year-over-year to 57600000.0 in Q1 2026; TTM through Mar 2026 was 221300000.0, a 374.89% decrease from a year earlier, with the FY2025 full-year figure at 80800000.0, up 59.38% from the prior year.
- Income from Continuing Operations grew to 57600000.0 in Q1 2026 per ARVN's latest filing, from 67400000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 82900000.0 in Q1 2025 and bottomed at 154800000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 63300000.0 (2022), against an average of 57300000.0.
- Across the five-year window, Income from Continuing Operations surged 219.45% in 2025 and sank 169.48% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 80100000.0 in 2022, then slumped by 93.26% to 154800000.0 in 2023, then jumped by 70.87% to 45100000.0 in 2024, then plunged by 49.45% to 67400000.0 in 2025, then advanced by 14.54% to 57600000.0 in 2026.
- Per Business Quant, the three latest ARVN Income from Continuing Operations figures stand at 57600000.0 (Q1 2026), 67400000.0 (Q4 2025), and 35100000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 498.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Arvinas | 512.64 Mn | -102.26 Mn | - | -57.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -57.60 Mn |
| Dec 31, 2025 | -67.40 Mn |
| Sep 30, 2025 | -35.10 Mn |
| Jun 30, 2025 | -61.20 Mn |
| Mar 31, 2025 | 82.90 Mn |
| Dec 31, 2024 | -45.10 Mn |
| Sep 30, 2024 | -49.20 Mn |
| Jun 30, 2024 | -35.20 Mn |
| Mar 31, 2024 | -69.40 Mn |
| Dec 31, 2023 | -154.80 Mn |
| Sep 30, 2023 | -63.90 Mn |
| Jun 30, 2023 | -65.30 Mn |
| Mar 31, 2023 | -80.80 Mn |
| Dec 31, 2022 | -80.10 Mn |
| Sep 30, 2022 | -63.30 Mn |
| Jun 30, 2022 | -67.50 Mn |
| Mar 31, 2022 | -61.10 Mn |
| Dec 31, 2021 | -46.10 Mn |
| Sep 30, 2021 | -46.80 Mn |
| Jun 30, 2021 | -50.30 Mn |